Proof of Principle in the Selective Treatment of Cancer by Antibody-Directed Enzyme Prodrug Therapy: The Development of a Highly Potent Prodrug This work was supported by the Deutsche Forschungsgemeinschaft (SFB 416) and by the Fonds der Chemischen Industrie.

Abstract

Perfectly adept for tumor treatment: With the seco-CBI-Q galactoside 1 a novel highly potent prodrug for the selective treatment of cancer using the ADEPT approach was developed, which shows very promising results in preclinical trials on a human bronchial carcinoma in SCID mice (see picture; lung tissue after (A) and before treatment (B)).